Medicare
HHS says Merck can’t sue over Medicare drug price talks
Merck & Co., a prominent pharmaceutical company, led the charge in challenging the contentious Medicare price negotiation provisions outlined in ...
Medicare Price Negotiations Could Slash Biotech R&D Spending, Gilead-Funded Study Warns
The Inflation Reduction Act (IRA) is projected to have a more significant impact on pharmaceutical research and development (R&D) than ...
Bracing for Change: CMS Unveils Drug Price Negotiation Targets Amid Industry Backlash
The day that pharmaceutical manufacturers have been cautiously eyeing has finally dawned – Tuesday saw the grand revelation of the ...
Medicare prescription coverage for obesity is supported by legislation by Novo Nordisk, Eli Lilly, and Boehringer Ingelheim
Despite the considerable excitement surrounding the potential of new and potent obesity medicines, these drugs remain inaccessible to many Americans ...
How will Medicare be affected by the cost of Leqembi from Eisai and Biogen? Sen. Sanders is curious
Senator Bernie Sanders (I-Vt.) is increasing his pressure on the US Department of Health and Human Services (HHS) regarding the ...
CMS introduces adjustments to Medicare price negotiation while maintaining a strong stance
The Centers for Medicare and Medicaid Services (CMS) has made some minor adjustments to its plan allowing Medicare to negotiate ...
PhRMA moves forward with the Medicare pricing talks
The National Infusion Centre Association, the Global Colon Cancer Association, and Pharmaceutical Research and Manufacturers of America (PhRMA) have all ...
